公开(公告)号：US11207409B2

公开(公告)日：2021-12-28

申请号：US15992852

申请日：2018-05-30

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Frederic A. Bourke, Jr. ,  Mark Dewhirst ,  Neil Spector ,  Paul Yoon ,  Justus Adamson ,  David Alcorta ,  Kim Lyerly ,  Leihua Liu ,  Takuya Osada ,  Mark Oldham ,  Zakaryae Fathi ,  Wayne F. Beyer ,  Harold Walder

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61K45/06 ,  A61K9/00 ,  A61N5/06 ,  A61N5/10 ,  A61K31/409 ,  A61P35/00

摘要： A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.

公开(公告)号：US09937178B2

公开(公告)日：2018-04-10

申请号：US14363346

申请日：2012-12-07

申请人： DUKE UNIVERSITY

发明人： Sally Kornbluth ,  Manabu Kurokawa ,  Neil Spector ,  Mark Dewhirst

IPC分类号： A61K31/517 ,  G01N33/50 ,  A61K39/395 ,  C07K16/32 ,  C12N15/113 ,  A61K45/06 ,  A61K31/496 ,  A61K31/404 ,  A61K31/407

CPC分类号： A61K31/517 ,  A61K31/404 ,  A61K31/407 ,  A61K31/496 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/32 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y603/02 ,  G01N33/5011 ,  G01N2800/52 ,  A61K2300/00

摘要： Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.

公开(公告)号：US20140336202A1

公开(公告)日：2014-11-13

申请号：US14363346

申请日：2012-12-07

申请人： DUKE UNIVERSITY

发明人： Sally Kornbluth ,  Manabu Kurokawa ,  Neil Spector ,  Mark Dewhirst

IPC分类号： A61K31/517 ,  A61K31/404 ,  G01N33/50 ,  A61K31/496

CPC分类号： A61K31/517 ,  A61K31/404 ,  A61K31/407 ,  A61K31/496 ,  A61K39/39558 ,  A61K45/06 ,  C07K16/32 ,  C12N15/1135 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y603/02 ,  G01N33/5011 ,  G01N2800/52 ,  A61K2300/00

摘要： Methods of treating subjects with cancer and screening for MDM2 inhibitors that may be effective cancer therapeutics are provided herein. The cancers that may be treated using MDM2 inhibitors using the methods described herein include those that are or may become resistant to treatment with tyrosine kinase inhibitors. Methods of treating subjects with cancers that have, or develop in response to treatment with tyrosine kinase inhibitors, elevated levels of MDM2, Mcl-1 or PP5 or decreased levels of Huwe1 or CAS using MDM2 inhibitors are provided herein. The MDM2 inhibitors may be effective at treating these cancers alone or in combination with a tyrosine kinase inhibitor regardless of p53 status (mutant or wild-type) of the cancer.

摘要翻译： 本文提供了治疗患有癌症的受试者和筛选可能是有效的癌症治疗剂的MDM2抑制剂的方法。 可以使用本文所述方法使用MDM2抑制剂治疗的癌症包括对酪氨酸激酶抑制剂进行治疗或可能变得耐药的癌症。 本文提供了治疗患有癌症受试者的方法，该癌症具有或响应于酪氨酸激酶抑制剂治疗而发展，MDM2，Mcl-1或PP5水平升高或使用MDM2抑制剂降低Huwe1或CAS的水平。 MDM2抑制剂可以有效地单独或与酪氨酸激酶抑制剂组合治疗这些癌症，而不管癌症的p53状态（突变体或野生型）如何。